This follow-up study assessed 44 out of the 47 patients from a previous trial who were diagnosed with Dupuytren's disease and randomized to undergo needle aponeurotomy and receive triamcinolone acetonide injections (NATI), or to undergo needle aponeurotomy (NA) alone. The purpose of this secondary analysis was to compare the long-term results and the need for re-treatment up to 53 months following the primary treatment procedure. The NATI group demonstrated significantly lower mean total active extension deficit (TAED) at 6 months, and 13 to 24 months, but no significant differences were noted from 25-53 months. Fewer patients in the NATI (7 patients; 30%) returned for re-treatment compared to the NA group (13 patients; 62%), but the difference between groups was not statistically significant (p=0.07).